Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,498 total articles
UPM-Kymmene still operates a high-quality forest-products franchise, but the combination of easing pulp-paper cyclical tailwinds, structural cost pressure and a lack of near-term value catalysts makes upside in 2026 increasingly narrow. This is a tactical trade idea to express that view while controlling downside.
Tower Semiconductor (TSEM) has gone from deep value to market darling as silicon photonics demand and AI networking partnerships accelerate. Fundamentals show real revenue momentum and expanding high-margin opportunities, but valuation is rich and the stock is volatile. This is a buy-the-story trade with a clear stop and a defined time horizon: par…
ODDITY Tech (ODD) plunged 49.2% to $14.74 after disclosing algorithm-driven ad-routing problems that materially raised customer acquisition costs and forced the company to guide Q1 2026 revenue down ~30% year-over-year. Jefferies' view that credit concerns outweigh the stock's apparent discount is the basis for a mid-term short: entry $14.74, targe…
Reckitt Benckiser (RBGLY) has retraced from its 52-week high into oversold territory. At $13.55 the stock trades at ~10.7x reported earnings with a 3.8% yield, an attractive entry for a mid-term rebound if macro sentiment stabilizes and litigation risk becomes clearer. This trade idea outlines an actionable long with entry, stop and targets, plus t…
UP Fintech (TIGR) looks mispriced relative to recent operating performance. The company reported accelerating revenue and large net income improvement in 2025, has a sub-$1.2B market cap, and trades near technical support with an oversold RSI. This trade proposes a controlled long with an entry at $6.50, stop at $5.80 and a target of $12.00 over a …
Richemont (CFRHF) trades on the OTC market with thin liquidity and a volatile short book. Technicals show an oversold setup (RSI ~30) while the 50-day moving average sits near $195. Short interest and days-to-cover metrics spiked to extreme levels into late Feb 2026, suggesting much downside risk has already been priced. This is a tactical long ide…
Applied Optoelectronics plunged after a sharp intraday reversal, creating a high-conviction swing trade. The company's first volume order exceeding $200M for 1.6T transceivers, a 210,000 sq. ft. Texas facility and plans to reach 500,000 combined 800G/1.6T monthly units are the fundamental catalysts. Valuation is rich, so risk is elevated; trade siz…
Nvidia’s combination of cash-rich fundamentals, management signaling around a $6 tokenomics construct, and still-substantial AI demand create a buyable asymmetric setup after the recent pullback. This trade idea lays out an entry at $172.50, a stop at $160.00, and a primary target of $210.00 over a mid-term horizon (45 trading days), with a longer-…
Coherent's strategic agreement with Nvidia, plus robust demand for optics in AI-optimized data centers, supports a renewed buy. The stock is offering a mid- to long-term entry after a sharp pullback; risk is elevated given rich valuation and near-term macro volatility.
S&P Global (SPGI) has seen its multiple compress from peak levels as cyclicality and investor rotation hit data-and-analytics names. Fundamentals remain intact: recurring revenues, strong free cash flow ($5.456B), and a return-on-equity north of 14%. With a market cap around $127B and a P/E near 29, the pullback is a chance to buy a high-quality fr…
Assembly Biosciences (ASMB) is a small-cap antiviral developer with a tight float, deep Gilead collaboration, and binary development catalysts ahead. We view a calibrated long position as favorable given the company’s optionality on helicase-primase inhibitor (HPI) programs and nascent HDV candidate work, balanced against negative cash flow and val…
Eli Lilly (LLY) is trading off recent highs despite dominant share in chronic weight-management drugs and compelling trial headlines. The combination of strong cash generation, blockbuster product momentum, and an oversold technical backdrop makes a measured long the highest-probability trade for the next 45 trading days. This plan lays out entry, …
Santos offers one of the cleanest pure plays on natural gas and LNG among mid-cap E&P names. Rising gas demand, constrained global supply and Santos' project pipeline create a favorable risk-reward in the medium term. This trade idea lays out a clear entry, stop and target with catalysts and risk management for a mid-term (45 trading days) swing.
Boeing's share price is trading on a fragile mix of program setbacks (Starliner criticisms), operational hits to its space business (ULA/Vulcan pause) and macro pressure from higher oil. Fundamentals show negative free cash flow, heavy leverage and an elevated valuation. We lay out a mid-term (45 trading days) short with precise entry, stop and tar…
Kraft Heinz (KHC) trades at roughly $21.76 with a market cap near $25.8B and reported free cash flow of $3.66B—implying a roughly 14% FCF yield. The valuation is compelling: price-to-free-cash-flow near 7.0, EV/EBITDA under 8 and P/B ~0.62. If management stabilizes revenue and margins modestly recover, the stock can re-rate meaningfully. This trade…
Cheniere is wired to win from contracted LNG volumes, capacity expansion and geopolitical supply shocks. Spot gas moves matter for headlines, but the company's economics are driven by long-term contracts, integrated terminals and strong free cash flow. The trade: pick a structured entry on a pullback, protect with a meaningful stop, and target a re…
Toast (TOST) looks like an asymmetric setup: the core restaurant SaaS business is gaining net new locations and ARR, free cash flow is meaningful, and a marquee investor has increased its stake — yet the shares trade near the low end of the 52-week range. I recommend a tactical long with a defined stop and a mid-term target to capture mean reversio…
Invivyd is a small-cap antibody specialist with a commercial COVID product (PEMGARDA) producing real revenue and a Phase 3 readout for vaccine-alternative VYD2311 expected mid-2026. Market cap is roughly $406M while the company reports accelerating quarterly product sales and has recently bolstered the balance sheet. This trade idea outlines an act…
Astera Labs has been a high-flying supplier to the AI data-center buildout, but today's price action and the capitalized expectations do not yet square with a pullback in sentiment. With a market cap near $20.4B, P/E north of 100, and EV/Sales approaching 25x, the setup looks vulnerable. We outline a swing short with clear entry, stop and target le…
Microsoft trades at a multitrillion-dollar valuation that assumes continued high-margin, high-growth outcomes while price-to-free-cash-flow and price-to-sales imply little room for execution slip. With heavy AI and cloud spending increasingly front-loaded and fundamentals showing stretched multiples, a mid-term short targets mean reversion toward t…
Goldman Sachs (GS) is trading at roughly $811.57 and offers a compelling risk/reward for a mid-term swing: attractive P/E and P/B relative to its history, robust free cash flow, and a business that benefits from market volatility. This idea lays out an entry at $811.57, a stop at $760.00, and a target of $900.00 with a preferred horizon of mid term…
Rocket Lab (RKLB) is trading at $69.75 after a pullback from its 52-week high. The company’s fast launch cadence, record 2025 revenue of $602M and a $1.85B backlog set the stage for high growth as Neutron development progresses toward a Q4 2026 debut. This trade idea proposes a speculative long: entry $69.75, stop $62.00, target $95.00 for a mid-te…
Micron just reported a blowout fiscal Q2 with revenue of $23.86B and net income near $13.8B as AI infrastructure drove HBM and data-center demand. The market is debating whether Micron's $25B+ fiscal 2026 capex derails margins or cements a multi-year lead. This trade idea takes a long stance: buy on weakness with defined risk and a 180-trading-day …
Uber is no longer just a ride-hail marketplace. With recent deals that include a $1.25B commitment to Rivian and deeper ties to Nvidia, Uber is positioning its demand network and capital-light deployment model to capture growth from autonomous vehicles. Fundamentals support a reasonably valued growth story: market cap roughly $153B, P/E ~16, positi…
Nvidia remains the essential supplier to the AI buildout. Fundamentals and cash generation support a constructive mid-term trade: enter around $176, stop $165, target $230 over the next 45 trading days. Valuation is rich but survivable given $96.7B in free cash flow and near-monopoly positions in datacenter GPUs and networking.
